Next Issue
Volume 13, January
Previous Issue
Volume 12, November
 
 

J. Cardiovasc. Dev. Dis., Volume 12, Issue 12 (December 2025) – 49 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Cover Story (view full-size image):
Order results
Result details
Section
Select all
Export citation of selected articles as:
13 pages, 823 KB  
Article
Advancing Minimally Invasive Mitral Valve Surgery: Early Outcomes of a Total Endoscopic 2D and 3D Approach
by Carlo Savini, Mariafrancesca Fiorentino, Diego Sangiorgi, Simone Calvi, Antonino Costantino, Elena Tenti and Elisa Mikus
J. Cardiovasc. Dev. Dis. 2025, 12(12), 501; https://doi.org/10.3390/jcdd12120501 - 18 Dec 2025
Viewed by 341
Abstract
Background: The minimally invasive approach is increasingly recognized as the standard for surgical management of mitral valve disease. Advances in endoscopic visualization and surgical instrumentation have enhanced precision while minimizing trauma, improving both functional and esthetic outcomes. This study presents a single-center experience [...] Read more.
Background: The minimally invasive approach is increasingly recognized as the standard for surgical management of mitral valve disease. Advances in endoscopic visualization and surgical instrumentation have enhanced precision while minimizing trauma, improving both functional and esthetic outcomes. This study presents a single-center experience with total endoscopic mitral valve repair (MVR) performed using two- or three-dimensional video-assisted technology. Methods: Between October 2022 and September 2025, 239 patients underwent total endoscopic MVR at our institution. Demographic, operative, and postoperative data were collected and analyzed. Results: Median age was 63 years, with 64.4% male. Median logistic EuroSCORE and EuroSCORE II were 2.53 and 0.83, respectively. Most patients were NYHA class II (54.4%), and 47.7% had pulmonary hypertension. Mitral annuloplasty was performed in 99.2% of cases; 78.6% received Gore-Tex chordae, 6.3% underwent posterior leaflet resection, and 11.7% edge-to-edge repair. Conversion to sternotomy occurred in 0.4%. In-hospital mortality was 1.3%; stroke occurred in 0.4%. Postoperative atrial fibrillation developed in 26.8%, while major complications such as sepsis (2.1%) and renal failure requiring dialysis (1.3%) were infrequent. Median ventilation time was 5 h, ICU stay was 2 days, and hospital stay was 7 days. Pre-discharge echocardiography showed ≤mild regurgitation in 99.2%. Conclusions: Total endoscopic MVR using two- or three-dimensional video assistance is safe, feasible, and yields excellent clinical, functional, and cosmetic results, with low morbidity and rapid recovery. Full article
(This article belongs to the Special Issue State of the Art in Mitral Valve Disease)
Show Figures

Graphical abstract

20 pages, 5348 KB  
Article
Early Cytoskeletal Remodeling Drives Hypertrophic Cardiomyopathy Pathogenesis in MYH6/7 Mutant hiPSC-Derived Cardiomyocytes
by Mohammad Shameem, Hassan Salih, Ahmed Sharara, Roshan Nicholas Rochus John, Leo Ogle and Bhairab N. Singh
J. Cardiovasc. Dev. Dis. 2025, 12(12), 500; https://doi.org/10.3390/jcdd12120500 - 17 Dec 2025
Viewed by 427
Abstract
Hypertrophic cardiomyopathy (HCM) is a common and deadly cardiac disease characterized by enlarged myocytes, increased myocardial wall thickening, and fibrosis. A majority of HCM cases are associated with mutations in the β-myosin heavy chain (MYH7) converter domain locus, which leads to [...] Read more.
Hypertrophic cardiomyopathy (HCM) is a common and deadly cardiac disease characterized by enlarged myocytes, increased myocardial wall thickening, and fibrosis. A majority of HCM cases are associated with mutations in the β-myosin heavy chain (MYH7) converter domain locus, which leads to varied pathophysiological and clinical manifestations. Using base-editing technology, we generated mutant human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) harboring HCM-causing myosin converter domain mutations (MYH7 c.2167C>T [R723C]; MYH6 c.2173C>T [R725C]) to define HCM pathogenesis in vitro. In this study, we integrated transcriptomic analysis with phenotypic and molecular analyses to dissect the HCM disease mechanisms using MYH6/7 myosin mutants. Our KEGG analysis of bulk RNA-sequencing data revealed significant upregulation of transcripts associated with HCM in the mutant hiPSC-CMs. Further, in-depth transcriptomic analysis using Gene-Ontology (GO-term) analysis for biological process showed upregulation of several transcripts associated with heart development and disease. Notably, our analysis showed robust upregulation of cytoskeletal transcripts, including actin-cytoskeleton networks, sarcomere components, and other structural proteins in the mutant CMs. Furthermore, cellular and nuclear morphological analysis showed that the MYH6/7 mutation induced cellular hypertrophy and increased aspect ratio compared to the isogenic control. Immunostaining experiments showed marked sarcomere disorganization with lower sarcomeric order and higher dispersion in the mutant hiPSC-CMs, highlighting the remodeling of the myofibril arrangement. Notably, the MYH6/7 mutant showed reduced cortical F-actin expression and increased central F-actin expression compared to the isogenic control, confirming the cytoskeletal remodeling and sarcomeric organization during HCM pathogenesis. These pathological changes accumulated progressively over time, underscoring the chronic and evolving nature of HCM driven by the MYH6/7 mutations. Together, our findings provide critical insights into the cellular and molecular underpinnings of MYH6/7-mutation-associated disease. These findings offer valuable insights into HCM pathogenesis, aiding in future therapies. Full article
(This article belongs to the Section Cardiac Development and Regeneration)
Show Figures

Graphical abstract

14 pages, 2225 KB  
Article
Genetic Spectrum, Clinical Characteristics, and Molecular Pathogenesis of Hypertrophic Cardiomyopathy Requiring Heart Transplantation
by Sofiya Andreeva, Lyubov Korneva, Mariya Marusova, Yulia Sazonova, Alexandra Gudkova, Anna Streltsova, Svetlana Fetisova, Maria Simonenko, Anna Fanta, Andrei Semenov, Maria Bortsova, Lubov Mitrofanova, Olga Moiseeva, Alexandr Bobylev, Lidiya Gavrilova, Ivan Vikhlyantsev, Petr Fedotov and Anna Kostareva
J. Cardiovasc. Dev. Dis. 2025, 12(12), 499; https://doi.org/10.3390/jcdd12120499 - 17 Dec 2025
Viewed by 309
Abstract
Hypertrophic cardiomyopathy (HCM) progressing to end-stage heart failure and heart transplantation (HT) is a rare clinical scenario with an insufficiently explored genetic background. In this single-center retrospective cohort study, we aimed to characterize the genetic spectrum, variants of HCM adverse remodeling, and aspects [...] Read more.
Hypertrophic cardiomyopathy (HCM) progressing to end-stage heart failure and heart transplantation (HT) is a rare clinical scenario with an insufficiently explored genetic background. In this single-center retrospective cohort study, we aimed to characterize the genetic spectrum, variants of HCM adverse remodeling, and aspects of molecular pathogenesis of this subgroup. The study included 14 patients (9 females), among whom 10 developed a dilated/hypokinetic phenotype and 4 a restrictive phenotype. In 13 patients (93%), at least one pathogenic or likely pathogenic genetic variant was identified. Dilated remodeling/hypokinesis was associated with loss-of-function variants in LAMP2 (3) in females, ALPK3homo (1), MYH7 (1), MYBPC3 (1), a heterozygous missense variant in TRIM63 (1), FLNCtv (1), TTNtv (2). For the latter two, electrophoretic analysis of titin isoform composition and protein content in myocardial fragments from explanted hearts confirmed the functional significance of TTN gene variants. The restrictive phenotype in the adult group was associated with carriage of multiple pathogenic sarcomere gene variants: MYL3homo (1), MYBPC3+TPM1 (1), an MYH7 converter domain variant (1), and, in one child, with a TNNT2 variant. This findings support HCM progressing to HT is characterized by a higher frequency of variants in non-sarcomeric genes and Danon disease compared to the general HCM cohort. Full article
Show Figures

Figure 1

20 pages, 6309 KB  
Review
Echocardiographic Assessment of Patients Undergoing Mitral Valve Repair
by Marco Rolando, Nadeem Elmasry, Federico Gobbi, Antonella Moreo, Nina Ajmone Marsan, Erberto Carluccio and Federico Fortuni
J. Cardiovasc. Dev. Dis. 2025, 12(12), 498; https://doi.org/10.3390/jcdd12120498 - 17 Dec 2025
Viewed by 536
Abstract
Mitral regurgitation (MR) is one of the most prevalent valvular disorders worldwide, with a growing burden driven by population aging and improved diagnostic capabilities. Understanding the mechanism of MR, whether primary, due to intrinsic valve abnormalities, or secondary, resulting from atrial or ventricular [...] Read more.
Mitral regurgitation (MR) is one of the most prevalent valvular disorders worldwide, with a growing burden driven by population aging and improved diagnostic capabilities. Understanding the mechanism of MR, whether primary, due to intrinsic valve abnormalities, or secondary, resulting from atrial or ventricular remodeling, is essential for optimal management. Echocardiography, particularly advanced modalities such as three-dimensional imaging and strain analysis, plays a central role in this process. It allows accurate quantification of MR severity, detailed characterization of valve and ventricular anatomy, and assessment of remodeling, all of which are critical for determining the optimal timing for intervention. Beyond diagnosis, echocardiography is indispensable in guiding therapy selection: it informs surgical planning by defining leaflet pathology for repair versus replacement strategies, and directs transcatheter interventions by guiding interatrial septal puncture, catheter orientation, and device deployment in real time. While surgery remains the gold standard for primary MR, transcatheter approaches including edge-to-edge repair and emerging mitral valve replacement are increasingly relevant, particularly in patients at high surgical risk or with complex anatomy. This review emphasizes the pivotal role of echocardiography in the pre-procedural assessment of MR, highlighting its ability to integrate anatomical, functional, and hemodynamic information to guide patient-tailored therapeutic strategies and optimize outcomes within a Heart Team framework. Full article
(This article belongs to the Special Issue State of the Art in Mitral Valve Disease)
Show Figures

Figure 1

19 pages, 5537 KB  
Review
Intravascular Imaging Guidance for Left Main Interventions: The Emerging Role of Optical Coherence Tomography
by Antonios Rigas Papapanagiotou, Antonios Karanasos, Athanasios Papageorgiou, Michail I. Papafaklis, Athanasios Moulias, Grigorios Tsigkas and Periklis Davlouros
J. Cardiovasc. Dev. Dis. 2025, 12(12), 497; https://doi.org/10.3390/jcdd12120497 - 17 Dec 2025
Viewed by 611
Abstract
Left main (LM) coronary artery disease remains a critical and high-risk clinical entity with considerable prognostic impact. While surgical revascularization has long been the standard of care, advances in percutaneous coronary intervention (PCI) techniques have significantly improved outcomes, challenging traditional treatment paradigms. Nevertheless, [...] Read more.
Left main (LM) coronary artery disease remains a critical and high-risk clinical entity with considerable prognostic impact. While surgical revascularization has long been the standard of care, advances in percutaneous coronary intervention (PCI) techniques have significantly improved outcomes, challenging traditional treatment paradigms. Nevertheless, PCI in LM lesions continues to be associated with increased rates of repeat revascularization. This has underscored the importance of precise procedural planning and stent optimization, for which intravascular imaging is central. Among available modalities, intravascular ultrasound (IVUS) is well-established and widely endorsed in clinical guidelines for LM PCI. Optical coherence tomography (OCT), although increasingly utilized in other coronary settings, has a more limited but growing body of evidence in LM disease. This review explores the evolving application of OCT in LM interventions, focusing on its capabilities in plaque characterization, vessel sizing, stent selection, and identification of failure mechanisms such as malapposition and underexpansion. In addition, it discusses the utility of OCT in guiding bifurcation strategies and provides a comparative assessment with IVUS, integrating the most recent clinical data. Full article
Show Figures

Figure 1

15 pages, 2151 KB  
Article
Development and Validation of an Acute Large Animal Model for Type A Aortic Dissection
by Ezin Deniz, Sibylle Marsen, Florian Helms, Heike Krüger, Naoki Arima, Jasmin Hanke, Ali Saad Merzah, Sadeq Al-Hasan-Al-Saegh, Sara Knigge, Saman Alhowaizy, Tanja Meyer, Rabea Hinkel, Morsi Arar, Aron F. Popov, Günes Dogan, Bastian Schmack, Alexander Weymann, Arjang Ruhparwar, Salaheldien Ali Mohamed-Glüer and Jan D. Schmitto
J. Cardiovasc. Dev. Dis. 2025, 12(12), 496; https://doi.org/10.3390/jcdd12120496 - 16 Dec 2025
Viewed by 271
Abstract
Background: Animal models are essential for translating diagnostic and therapeutic strategies into clinical practice and offer valuable insights into the pathophysiology of diseases such as aortic dissection. This study presents a novel acute in vivo large animal model of Stanford type A aortic [...] Read more.
Background: Animal models are essential for translating diagnostic and therapeutic strategies into clinical practice and offer valuable insights into the pathophysiology of diseases such as aortic dissection. This study presents a novel acute in vivo large animal model of Stanford type A aortic dissection, combining open surgical access with endovascular techniques to leverage the advantages of both. The model aims to reproducibly simulate acute dissections in swine, providing a standardized platform for evaluating diagnostics, disease mechanisms, and treatment strategies. Methods: Six pigs underwent a standardized protocol to induce aortic dissection. Arterial pressure was monitored via femoral and carotid catheterization. A conventional sternotomy was performed, followed by tangential cross-clamping of the ascending aorta and a controlled incision proximal to the brachiocephalic trunk. The intima and the media were separated using a guidewire and catheter-based technique to create a false lumen. A re-entry tear was also established to allow for controlled intraluminal access. Animals were monitored for 12 h post-intervention, with serial blood sampling. At the end of the experiment, the animals were euthanized and the aortas harvested for macroscopic and histological analysis. Results: In all 6 animals, the placement of arterial catheters in femoral and carotid arteries, as well as the sternotomy, was established without any complications. The dissection model was successfully created in 5 out of 6 animals by clinical signs such as adventitial hematoma, macroscopic wall separation and/or decreased femoral blood pressure. One animal experienced complete aortic perforation. Five animals completed the full observation period of 12 h. Conclusion: A standardized, reproducible, and robust large animal model of acute Stanford type A aortic dissection using a hybrid approach was developed. This model closely simulates the clinical and pathological features of human aortic dissection, making it a valuable tool for preclinical research in diagnostics, pathophysiology, and treatment development. Full article
(This article belongs to the Special Issue Aortic Surgery—Back to the Roots and Looking to the Future)
Show Figures

Figure 1

15 pages, 16928 KB  
Article
Virtual Reality to Enhance Understanding of Congenital Heart Disease
by Shanti L. Narasimhan, Ali H. Mashadi, Syed Murfad Peer, Kishore R. Raja, Pranava Sinha, Satoshi Miyairi, Juan Carlos Samayoa Escobar, Devin Chetan, Yu-Hui Huang and Paul A. Iaizzo
J. Cardiovasc. Dev. Dis. 2025, 12(12), 495; https://doi.org/10.3390/jcdd12120495 - 15 Dec 2025
Viewed by 356
Abstract
This retrospective study evaluated the clinical utility of Virtual Reality (VR) in visualizing extracardiac CHD (eCHD) abnormalities involving great vessels, pericardium, or structures outside the heart in nine pediatric patients. Anonymized computed tomography angiography (CTA) DICOM images were processed using Elucis (Version 1.10 [...] Read more.
This retrospective study evaluated the clinical utility of Virtual Reality (VR) in visualizing extracardiac CHD (eCHD) abnormalities involving great vessels, pericardium, or structures outside the heart in nine pediatric patients. Anonymized computed tomography angiography (CTA) DICOM images were processed using Elucis (Version 1.10 elucis next) software to generate interactive 3D models via segmentation. VR models were reviewed for a variety of cases: vascular rings (two with right aortic arch, aberrant left subclavian artery, and diverticulum of Kommerell; two with double aortic arch), pericardial teratomas (n = 2), right superior vena cava draining into the left atrium (n = 1), left pulmonary artery sling (n = 1), and aortopulmonary window (n = 1). VR video images were presented during weekly heart center conferences. A survey conducted among heart center staff assessed the perceived value of VR in clinical practice. A total of 62% found traditional diagnostic modalities very effective, 100% considered VR a valuable diagnostic tool, 65% responded positively to VR image resolution, 50% highlighted its educational benefit, 81% believed VR enhanced diagnostic accuracy and surgical planning, and 100% would recommend its use to colleagues. This study demonstrates the successful integration of VR-based segmentation into clinical workflows, underlining its potential as both an educational resource and a tool to support diagnostic and surgical decision-making. Full article
(This article belongs to the Section Pediatric Cardiology and Congenital Heart Disease)
Show Figures

Figure 1

15 pages, 1192 KB  
Article
Females and Exercise Capacity Impairment in Heart Failure: A Sex-Focused Analysis
by Ainhoa Lorenzo, Raúl Ramos-Polo, Laia Lorenzo-Esteller, Xinying Lin, Emma Barragan, Paula Aranda, Èlia Boixader, Foix Regull, Nerea Martín, Ariana Ollé, Marc Llagostera, Núria José-Bazán, Pedro Moliner, Cristina Enjuanes and Josep Comin-Colet
J. Cardiovasc. Dev. Dis. 2025, 12(12), 494; https://doi.org/10.3390/jcdd12120494 - 14 Dec 2025
Viewed by 322
Abstract
Heart failure (HF) is becoming increasingly common, especially in older females, and displays marked sex-related differences in pathophysiology, treatment, and outcomes. Submaximal exercise capacity (SEC), frequently measured by the six-minute walk test (6MWT), is an important marker of aerobic function, prognosis, and quality [...] Read more.
Heart failure (HF) is becoming increasingly common, especially in older females, and displays marked sex-related differences in pathophysiology, treatment, and outcomes. Submaximal exercise capacity (SEC), frequently measured by the six-minute walk test (6MWT), is an important marker of aerobic function, prognosis, and quality of life in HF. However, evidence regarding sex differences in SEC remains limited and inconsistent. This single-centre, prospective cohort study included 1069 patients with chronic HF enrolled between 2004 and 2014. SEC was assessed using the 6MWT, and extensive clinical and psychosocial data were collected. Multivariate models evaluated the independent association between sex and SEC. Results showed that females had significantly shorter 6MWT distances (155 ± 149 m) than males (265 ± 164 m; p < 0.001). Female sex was an independent predictor of impaired SEC in both unadjusted and adjusted analyses (odds ratios 2.226–3.609; p < 0.001). Additional determinants of reduced SEC included advanced age, higher NYHA class, elevated heart rate, diabetes, iron deficiency, dependence in activities of daily living, cognitive impairment, and depressive symptoms. These findings demonstrate that female sex is a strong, independent predictor of reduced functional capacity in chronic HF and emphasize the need for sex-specific strategies addressing both clinical and psychosocial factors to improve outcomes. Full article
Show Figures

Figure 1

14 pages, 636 KB  
Review
Coronary Computed Tomography Angiography to Exclude Acute Coronary Syndrome in Low-Risk Chest Pain Patients
by Lauren Ling, Asim Shaikh and Matthew Sibbald
J. Cardiovasc. Dev. Dis. 2025, 12(12), 493; https://doi.org/10.3390/jcdd12120493 - 14 Dec 2025
Viewed by 389
Abstract
Background: Coronary computed tomography angiography (CCTA) is a non-invasive imaging tool used predominantly in suspected chronic coronary artery disease (CAD) patients, due to its high negative predictive value. However, increasing focus has been placed on CCTA to manage and risk stratify acute chest [...] Read more.
Background: Coronary computed tomography angiography (CCTA) is a non-invasive imaging tool used predominantly in suspected chronic coronary artery disease (CAD) patients, due to its high negative predictive value. However, increasing focus has been placed on CCTA to manage and risk stratify acute chest pain patients in emergency departments (ED). Objective: This scoping review summarizes the available evidence on the role of CCTA to exclude acute coronary syndrome (ACS) in low-risk acute chest pain patients, focusing on its diagnostic accuracy, safety, and application in the context of high sensitivity cardiac troponin assays (hs-cTn). Methods: Articles published between January 2015 and March 2025 investigating CCTA use in low-risk acute chest pain patients were retrieved from Medline, Embase, Emcare, and Web of Science databases. Results: 22 articles (13,617 patients) were retrieved. CCTA had strong diagnostic performance, with an excellent negative predictive value (99.8–100%) and sensitivity (94–100%) for ACS diagnosis and prediction of major adverse cardiovascular events. Specificity and positive predictive values were lower and less consistent. When combined with hs-cTn, the diagnostic accuracy of CCTA for ACS was improved significantly. CCTA was associated with low rates of ACS at follow-up (0–3.5%), which were lower than or comparable to the safety outcomes of standard care and stress testing. Full article
Show Figures

Figure 1

11 pages, 932 KB  
Article
Genetic and Clinical Characterization of FLNC Variants in Chinese Patients with Cardiomyopathy
by Guofeng Xing, Li Chen, Lizhi Lv, Chengming Hu, Shengmei Liu, Yabing Duan, Jiachen Li, Qiang Wang and Xiaoyan Li
J. Cardiovasc. Dev. Dis. 2025, 12(12), 492; https://doi.org/10.3390/jcdd12120492 - 12 Dec 2025
Viewed by 354
Abstract
This study investigates FLNC mutations in Chinese cardiomyopathy patients. Background: Inherited cardiomyopathies, including dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and arrhythmogenic right ventricular cardiomyopathy (ARVC) are major heart failure causes. FLNC, critical for muscle structure, is implicated in myofibrillar myopathy [...] Read more.
This study investigates FLNC mutations in Chinese cardiomyopathy patients. Background: Inherited cardiomyopathies, including dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and arrhythmogenic right ventricular cardiomyopathy (ARVC) are major heart failure causes. FLNC, critical for muscle structure, is implicated in myofibrillar myopathy and isolated DCM (3–4% cases) with ventricular arrhythmias. Missense variants are linked to HCM and protein aggregation. A cohort of 25 patients with pathogenic/likely pathogenic FLNC mutations (2022–2025, Beijing Anzhen Hospital) underwent whole-exome sequencing (WES) using IDT kit 1.0/Hiseq 4000. Variants were classified via the American College of Medical Genetics and Genomics (ACMG) guidelines. Clinical data (echocardiography, CMR, labs) and follow-up data (prognosis, meds, and family history) were collected. The statistics used SPSS (p < 0.05). The mean age was 38 ± 14.6 years (13 males). There were 25 FLNC mutations: 12 single nucleotide polymorphisms (SNPs), 5 deletions, 2 duplications, and 3 deletion-insertions, classified as 6 pathogenic, 16 likely pathogenic, and 3 variants of uncertain significance (VUS). Diagnoses: 24% dilated cardiomyopathy (DCM), 8% hypertrophic cardiomyopathy (HCM), and 4% left ventricular non-compaction. Nonsense mutation carriers exhibited significantly higher tricuspid regurgitation prevalence compared to frameshift mutation carriers (6/9 vs. 2/10; p = 0.04). Echocardiography revealed reduced left ventricular ejection fraction (LVEF) (41.5 ± 14.1%), with statistically significant differences in fractional shortening (p = 0.024) and aortic root diameter (p = 0.028). Pedigree analysis confirmed that a frameshift mutation (LP) co-segregated with familial DCM and was associated with severe phenotypes, including sudden cardiac death. Furthermore, nonsense FLNC mutations correlated with increased tricuspid regurgitation severity, smaller aortic root dimensions, and reduced pulmonary artery flow velocity. Full article
Show Figures

Figure 1

10 pages, 440 KB  
Systematic Review
Open Heart Mitral Valve Replacement Using Transcatheter Heart Valves for Severe Mitral Annular Calcification—A Literature Review
by Michele D’Alonzo, Massimo Baudo, Francesco Cabrucci, Francesca Maria di Muro, Dimitrios E. Magouliotis, Beatrice Bacchi, Arian Arjomandi Rad, Andrew Xanthopoulos and Tulio Caldonazo
J. Cardiovasc. Dev. Dis. 2025, 12(12), 491; https://doi.org/10.3390/jcdd12120491 - 12 Dec 2025
Viewed by 446
Abstract
Mitral annular calcification makes conventional mitral valve surgery extremely challenging and has led to growing interest in less invasive alternatives such as transcatheter mitral valve replacement. Alongside percutaneous approaches, some centers have explored open transatrial implantation of transcatheter heart valves in patients with [...] Read more.
Mitral annular calcification makes conventional mitral valve surgery extremely challenging and has led to growing interest in less invasive alternatives such as transcatheter mitral valve replacement. Alongside percutaneous approaches, some centers have explored open transatrial implantation of transcatheter heart valves in patients with heavily calcified annuli. This systematic review examines the current evidence on this hybrid “valve-in-MAC” technique, tracing its clinical evolution, technological refinements, patient outcomes, and ongoing debates. Key themes emerging from the literature include the adaptation of existing balloon-expandable and mitral-specific devices to the complex anatomy of calcified mitral annuli, the open transatrial approach as a safer alternative to extensive surgical debridement, and advances in imaging and device design aimed at reducing left ventricular outflow tract obstruction and paravalvular leak. Persistent uncertainties remain, particularly regarding patient selection, long-term valve performance, and comparisons with conventional surgical repair or replacement. Although open transatrial implantation appears technically feasible and provides favorable hemodynamic results compared with fully percutaneous procedures, reported 30-day mortality remains high (approximately 19–27%). This reflects the advanced age, frailty, and multiple comorbidities typical of this patient group rather than procedural shortcomings. Current evidence is limited, with few comparative studies and little data on valve durability. Future work should prioritize multicenter prospective registries and well-designed comparative studies to better define the role of this emerging salvage strategy. Full article
(This article belongs to the Special Issue State of the Art in Mitral Valve Disease)
Show Figures

Figure 1

21 pages, 792 KB  
Systematic Review
Risk Factors and Preventing Strategies of Pocket Hematoma After Cardiac Implantable Electronic Device Implantation: A Systematic Review
by Siyin Ding and Xiaohong Pan
J. Cardiovasc. Dev. Dis. 2025, 12(12), 490; https://doi.org/10.3390/jcdd12120490 - 12 Dec 2025
Viewed by 656
Abstract
Pocket hematoma is a common complication following cardiac implantable electronic device (CIED) implantation, traditionally perceived as a manageable local issue. Accumulating evidence, however, indicates that clinically significant pocket hematoma (CSH) is strongly associated with increased infection rates, elevated healthcare costs, and heightened mortality. [...] Read more.
Pocket hematoma is a common complication following cardiac implantable electronic device (CIED) implantation, traditionally perceived as a manageable local issue. Accumulating evidence, however, indicates that clinically significant pocket hematoma (CSH) is strongly associated with increased infection rates, elevated healthcare costs, and heightened mortality. Key risk factors include advanced age, low body mass index (BMI), chronic kidney disease, complex procedures (device upgrades/replacements) and periprocedural antithrombotic management, particularly uninterrupted dual antiplatelet therapy (DAPT) and heparin/low-molecular-weight heparin (LMWH) bridging strategies, which significantly elevate bleeding risk compared to continued vitamin K antagonist (VKA) therapy or direct oral anticoagulant (DOAC) protocols. Novel compression devices and topical hemostatic agents show promise for prevention, while standardized definitions and risk stratification tools are urgently needed. This review synthesizes current evidence on multifactorial pathogenesis, adverse outcomes, and evolving preventive strategies for pocket hematoma, emphasizing its underappreciated clinical significance and the critical need for optimized periprocedural management in high-risk patients. Full article
Show Figures

Figure 1

15 pages, 1093 KB  
Review
A Proposed Algorithm for the Management of Patients with Cardiogenic Shock Based on Contemporary Knowledge and Gaps in Evidence
by Aidonis Rammos, Christos D. Floros, Ioannis Tzourtzos, Ilektra E. Stamou, Petros Kalogeras, Ioanna Samara, Konstantinos C. Siaravas, Vasileios Bouratzis, Aris Bechlioulis, Xenofon M. Sakellariou, Katerina K. Naka and Lampros K. Michalis
J. Cardiovasc. Dev. Dis. 2025, 12(12), 489; https://doi.org/10.3390/jcdd12120489 - 11 Dec 2025
Viewed by 1568
Abstract
Cardiogenic shock (CS) is a heterogeneous pathophysiological state with high mortality, despite the development of cardiac intensive care units (CICUs) and the advanced treatments applied. The cornerstones of therapy that have been proposed in many algorithms are intravenous (i.v.) pressors and devices for [...] Read more.
Cardiogenic shock (CS) is a heterogeneous pathophysiological state with high mortality, despite the development of cardiac intensive care units (CICUs) and the advanced treatments applied. The cornerstones of therapy that have been proposed in many algorithms are intravenous (i.v.) pressors and devices for mechanical circulatory support (MCS), depending on the CS profile (left, right, or biventricular involvement), etiology (acute myocardial infarction, heart failure, or other) and SCAI stage (A to E, with MCS generally recommended for Stages C–E). There are many gaps in the evidence regarding i.v. medications and devices, with the existing data being controversial. Moreover, there are differences in the devices’ availability and, as a result, a lack of experience in many centers. In this review article, an algorithm for the management of CS is proposed, and the gaps in every step are presented. Early clinical suspicion that leads to prompt diagnosis, health system organization, large-scale trials, and the configuration of national or regional shock centers could bridge the current therapeutic gaps and balance disparities in the management of CS in order to improve outcomes. Full article
(This article belongs to the Special Issue Emerging Trends and Advances in Interventional Cardiology)
Show Figures

Figure 1

16 pages, 4234 KB  
Article
Cardiac Deformation Patterns During Exercise in Healthy Children
by Dario Collia, Ling Li, Mary Craft, Christopher C. Erickson, Zahi A. Fayad, Maria G. Trivieri, Jason Christensen and Gianni Pedrizzetti
J. Cardiovasc. Dev. Dis. 2025, 12(12), 488; https://doi.org/10.3390/jcdd12120488 - 10 Dec 2025
Viewed by 268
Abstract
In the cardiovascular system, geometric remodeling of the cardiac chambers is the main mechanism enabling increased cardiac performance during exercise in athletes, as well as underlying pathological progression toward heart failure. In this study, we investigated cardiac mechanics in healthy children across five [...] Read more.
In the cardiovascular system, geometric remodeling of the cardiac chambers is the main mechanism enabling increased cardiac performance during exercise in athletes, as well as underlying pathological progression toward heart failure. In this study, we investigated cardiac mechanics in healthy children across five phases of physical exercise, Rest, Mid, Peak, and Recovery, at 5 and 10 min, using three-dimensional echocardiography. Analyses were conducted relative to a reference cohort of healthy children to identify exercise-induced modifications that may contribute to cardiac remodeling. Ventricular performance was assessed through two complementary approaches: myocardial deformation, quantified by the principal values and directions of the strain tensor, and intraventricular flow dynamics, including assessments of ventricular filling patterns as the vorticity, vortex formation time and hemodynamic forces. This preliminary study offers promising insights into early cardiac function changes that may inform our understanding of cardiac remodeling during adaptation, healing or disease progression. Full article
Show Figures

Figure 1

12 pages, 950 KB  
Article
Minimally Invasive Multivessel Coronary Artery Bypass Grafting Using Total Coronary Revascularization via Left Anterior Minithoracotomy in Octogenarians
by Christian Sellin, Marius Grossmann, Ahmed Belmenai, Margit Niethammer, Hilmar Dörge and Volodymyr Demianenko
J. Cardiovasc. Dev. Dis. 2025, 12(12), 487; https://doi.org/10.3390/jcdd12120487 - 10 Dec 2025
Viewed by 506
Abstract
Background: A sternum-sparing approach of minimally invasive total coronary revascularization via left anterior thoracotomy (TCRAT) demonstrated favorable early and midterm results in unselected patients with coronary artery multivessel disease. However, safety and outcomes in elderly patients remain less well defined. Particularly in octogenarians [...] Read more.
Background: A sternum-sparing approach of minimally invasive total coronary revascularization via left anterior thoracotomy (TCRAT) demonstrated favorable early and midterm results in unselected patients with coronary artery multivessel disease. However, safety and outcomes in elderly patients remain less well defined. Particularly in octogenarians with relevant comorbidities, data are scarce, and the role of TCRAT compared to conventional coronary artery bypass grafting (CABG) remains uncertain. This study aimed to evaluate in-hospital and midterm outcomes of TCRAT in patients aged ≥ 80 years. Method: From 11/2019 to 10/2025, CABG via left anterior minithoracotomy on cardiopulmonary bypass and cardioplegic arrest was performed as a routine procedure in 859 consecutive, nonemergency patients. Among them, 82 patients (9.5%) were octogenarians, all presenting with multivessel coronary artery disease. Results: In the group of octogenarians, mean BMI was 26.5 ± 3.1 kg/m2, left ventricular ejection fraction was 49.2 ± 9.1% (range 20–55%), and mean EuroSCORE II was 5.1 ± 2.4. Comorbidities included diabetes mellitus (24.4%), chronic lung disease (7.3%), prior PCI (23.2%), and peripheral vascular disease (78.5%). The mean follow-up (100%) was 9.1 months. Left internal thoracic artery was used in 98.8% and radial artery was used in 43.9%. A mean of 3.0 ± 0.9 (range 2–5) anastomoses per patient was performed. Total operation time was 299 ± 64 min (range 164–480). In-hospital mortality was 1.2%, stroke rate was 1.2%, myocardial infarction rate was 0%, and repeat revascularization rate was 1.2%. At follow-up, all-cause mortality, myocardial infarction, repeat revascularization, and stroke were 4.9%, 0%, 2.4%, and 1.2%, respectively. The overall major adverse cardiac and cerebrovascular events rate (MACCE) was 7.3% at follow-up. Conclusion: TCRAT enables complete coronary artery revascularization in multivessel coronary artery disease without sternotomy and can be safely performed in octogenarians. Both in-hospital and midterm outcomes were favorable and comparable to reported contemporary outcomes of conventional CABG in elderly patients. Full article
(This article belongs to the Special Issue Minimally Invasive Coronary Revascularization: State of the Art)
Show Figures

Graphical abstract

17 pages, 1689 KB  
Article
Shifting Determinants of Mortality Risk After Orthotopic Heart Transplantation Identified by Machine Learning
by Kinga Bianka Koritsánszky, Rita Szentgróti, Ádám Szijártó, Márton Tokodi, Alexandra Vereb, Andrea Kőszegi, Balázs Sax, Attila Kovács, Béla Merkely and Andrea Székely
J. Cardiovasc. Dev. Dis. 2025, 12(12), 486; https://doi.org/10.3390/jcdd12120486 - 10 Dec 2025
Viewed by 255
Abstract
Background: Orthotopic heart transplantation (OHT) remains the gold standard for end-stage heart failure, yet individualized risk assessment for postoperative mortality remains challenging. We aimed to develop and interpret random forest-based models for predicting 30-day and 1-year mortality and to examine whether the key [...] Read more.
Background: Orthotopic heart transplantation (OHT) remains the gold standard for end-stage heart failure, yet individualized risk assessment for postoperative mortality remains challenging. We aimed to develop and interpret random forest-based models for predicting 30-day and 1-year mortality and to examine whether the key predictors differ between the 30-day and 1-year models. Methods: We analyzed 581 patients who underwent OHT between 2012 and 2024. The 30-day and 1-year mortality rates were 9.9% and 17.6%, respectively. Eighty-seven preoperative and forty-eight postoperative variables were considered as input features for model development. Random forest models were trained and validated using five-fold cross-validation, and explainability was assessed using SHapley Additive exPlanations (SHAP). Results: Using preoperative features only, the random forest models achieved AUCs of 0.62 (95% CI, 0.48–0.75) for 30-day and 0.67 (95% CI, 0.56–0.78) for 1-year mortality. SHAP analysis revealed that early mortality predictions were primarily driven by features reflecting acute physiological stress—hepatic dysfunction, inflammation, and hemodynamic instability—whereas long-term predictions were increasingly influenced by renal function, metabolic reserve, and frailty. Incorporating postoperative features improved performance (AUC 0.98 [95% CI, 0.97–0.99] and 0.86 [95% CI, 0.80–0.92], respectively), with model predictions dominated by the severity and persistence of organ dysfunction: short-term risk driven by hepatic injury, hemodynamic compromise, and critical illness, and long-term risk by sustained hepatic and renal impairment, metabolic resilience, and duration of circulatory support. Conclusions: Random forest models integrating preoperative and immediate postoperative data could predict short- and mid-term mortality after OHT. SHAP analysis demonstrated temporal shifts in the most important predictors, supporting the role of dynamic, data-driven risk assessment in transplant care. Full article
(This article belongs to the Special Issue Artificial Intelligence in Cardiac Surgery and Heart Transplantation)
Show Figures

Graphical abstract

12 pages, 735 KB  
Article
Long-Term Mortality and Survival in Patients with Acute Heart Failure Assessed by Emergency Medical Services
by Enrique Castro-Portillo, Ana Ramos-Rodríguez, Raúl López-Izquierdo, Irene Bermudez-Castellanos, Miguel Á. Castro Villamor, Santiago Otero de la Torre, Francisco T. Martínez Fernández, Irene Sánchez Soberon, Ancor Sanz-García and Francisco Martín-Rodríguez
J. Cardiovasc. Dev. Dis. 2025, 12(12), 485; https://doi.org/10.3390/jcdd12120485 - 10 Dec 2025
Viewed by 358
Abstract
Background: Acute heart failure (AHF) is a common reason for emergency care, yet data on its epidemiology and prognosis in the prehospital setting remain limited. This study aims to analyze the characteristics and long-term survival outcomes of patients with AHF managed by emergency [...] Read more.
Background: Acute heart failure (AHF) is a common reason for emergency care, yet data on its epidemiology and prognosis in the prehospital setting remain limited. This study aims to analyze the characteristics and long-term survival outcomes of patients with AHF managed by emergency medical services (EMSs). Methods: A multicenter, prospective, observational study was conducted in adult patients attended by EMSs and transferred to emergency departments (EDs). Collected data included demographics, vital signs, laboratory parameters, chronic obstructive pulmonary disease (COPD) history, comorbidity burden assessed using the Age-adjusted Charlson Comorbidity Index (aCCI), and clinical outcomes. The primary endpoint was 2-year mortality (M2Y). Survival analysis was performed using Cox regression and Kaplan–Meier analysis. Results: A total of 417 patients were included. Their median age was 84 years, and 48.2% were women. A total of 92.3% of the patients had an elevated aCCI. Overall, M2Y was 57.6%, rising to 74.4% among COPD patients. aCCI range and elevated plasma potassium and lactate levels were independently associated with reduced survival (HR 2.86, 1.45 and 1.15, respectively). Overall, 50% of all deaths occurred within the first 49 days. Conclusions: AHF patients attended by EMSs exhibited high 2-year mortality, likely due to advanced age and comorbidities. High comorbidity burden and abnormal potassium and lactate levels were linked to worse outcomes. Full article
Show Figures

Figure 1

38 pages, 636 KB  
Review
Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022–2025
by Michał Wilk and Rafał Tymków
J. Cardiovasc. Dev. Dis. 2025, 12(12), 484; https://doi.org/10.3390/jcdd12120484 - 10 Dec 2025
Viewed by 2689
Abstract
Heart failure (HF) remains a major challenge in cardiovascular medicine, contributing to high global rates of hospitalization and mortality. Recent research (2022–2025) has emphasized its heterogeneity, highlighting distinct phenotypes—HFpEF, HFmrEF, and HFrEF—driven by mechanisms such as chronic inflammation, myocardial fibrosis, and neurohormonal imbalance. [...] Read more.
Heart failure (HF) remains a major challenge in cardiovascular medicine, contributing to high global rates of hospitalization and mortality. Recent research (2022–2025) has emphasized its heterogeneity, highlighting distinct phenotypes—HFpEF, HFmrEF, and HFrEF—driven by mechanisms such as chronic inflammation, myocardial fibrosis, and neurohormonal imbalance. Advances in therapy, particularly with sodium–glucose cotransporter-2 inhibitors (SGLT2i), angiotensin receptor–neprilysin inhibitors (ARNI), and iron supplementation, have reshaped treatment strategies. Moreover, the growing recognition of overlaps between HF and cardiomyopathies such as hypertrophic, Takotsubo, and amyloidosis underscores the need for integrated care. This review summarizes recent findings from leading journals, mapping the evolving understanding of HF pathophysiology and management, and outlining emerging directions for research and clinical practice. Full article
(This article belongs to the Special Issue Heart Failure: Clinical Diagnostics and Treatment, 2nd Edition)
Show Figures

Graphical abstract

16 pages, 1896 KB  
Review
Left Atrial Appendage Closure Versus Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis
by Chen Wang, Dan Zhu, Jinliang Nan and Danyang Zhang
J. Cardiovasc. Dev. Dis. 2025, 12(12), 483; https://doi.org/10.3390/jcdd12120483 - 8 Dec 2025
Viewed by 610
Abstract
Background: Left atrial appendage (LAA) closure is an alternative to oral anticoagulants (OAC) for stroke prevention in atrial fibrillation (AF), but comparative evidence remains inconsistent. This study systematically evaluates the efficacy and safety of LAA closure versus OAC in AF patients. Methods: We [...] Read more.
Background: Left atrial appendage (LAA) closure is an alternative to oral anticoagulants (OAC) for stroke prevention in atrial fibrillation (AF), but comparative evidence remains inconsistent. This study systematically evaluates the efficacy and safety of LAA closure versus OAC in AF patients. Methods: We systematically searched PubMed, EmBase, Cochrane Library, and Web of Science for randomized controlled trials (RCTs) and propensity score-matched (PSM) studies published up to 30 September 2025. Treatment effects were estimated using relative risks (RR) with 95% confidence intervals (CI), and a random-effects model was applied for all analyses. Results: Fifteen studies (17,116 AF patients) were included, comprising 4 RCTs, 3 prospective PSM studies, and 8 retrospective PSM studies. Compared with OAC, LAA closure significantly reduced the composite endpoint (RR: 0.79; 95% CI: 0.66–0.95; p = 0.010), all-cause mortality (RR: 0.58; 95% CI: 0.49–0.69; p < 0.001), and cardiovascular mortality (RR: 0.55; 95% CI: 0.44–0.67; p < 0.001). Risks of any stroke (RR: 1.06; 95% CI: 0.86–1.31; p = 0.555), ischemic stroke (RR: 1.00; 95% CI: 0.85–1.17; p = 0.972), hemorrhagic stroke (RR: 0.96; 95% CI: 0.54–1.70; p = 0.879), and major bleeding (RR: 0.84; 95% CI: 0.67–1.04; p = 0.112) were not significantly different between groups. Conclusions: In AF patients, LAA closure significantly reduces mortality and a composite clinical endpoint compared to OAC, with similar risks of stroke and major bleeding. It is a favorable alternative for patients unsuitable for long-term anticoagulation. Full article
Show Figures

Graphical abstract

10 pages, 366 KB  
Case Report
Reduced Ejection Fraction of the Systemic Right Ventricle and Severe Tricuspid Regurgitation: Medication or Surgery?
by Anton V. Minaev, Timur Y. Danilov, Diana P. Paraskevova, Vera I. Dontsova, Inna I. Trunina, Viktor B. Samsonov, Sofya M. Tsoy, Alexander S. Voynov and Julia A. Sarkisyan
J. Cardiovasc. Dev. Dis. 2025, 12(12), 482; https://doi.org/10.3390/jcdd12120482 - 8 Dec 2025
Viewed by 364
Abstract
(1) Background: The systemic right ventricular (SRV) dysfunction and severe tricuspid regurgitation (TR) remain significant challenges in patients with congenitally corrected transposition of the great arteries (ccTGA) or following atrial switch procedures. Currently, there is no established, evidence-based medical therapy specifically designed for [...] Read more.
(1) Background: The systemic right ventricular (SRV) dysfunction and severe tricuspid regurgitation (TR) remain significant challenges in patients with congenitally corrected transposition of the great arteries (ccTGA) or following atrial switch procedures. Currently, there is no established, evidence-based medical therapy specifically designed for SRV failure, and treatment approaches are largely extrapolated from left ventricular heart failure (HF) guidelines. This therapeutic gap highlights the need for tailored pharmacologic strategies and optimized perioperative management in this unique population. The optimal timing of surgical intervention and the role of modern HF therapy are still under active investigation. (2) Methods: We present a case series of four patients (three adults and one child) with SRV dysfunction and severe TR, who underwent staged treatment consisting of optimized medical therapy followed by surgical tricuspid valve (TV) replacement. Medical therapy included positive inotropes, sacubitril/valsartan, sodium-glucose co-transporter 2 inhibitors (iSGLT2), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and loop diuretics. (3) Results: All patients demonstrated clinical and hemodynamic improvement prior to surgery, with an increase in systemic ventricular ejection fraction (SVEF > 40%) and cardiac index. TV replacement was performed with favorable early postoperative outcomes and preserved ventricular function at mid-term follow-up. No mortality or major adverse events occurred during follow-up. One case of acute cystitis was associated with dapagliflozin. In all patients, postoperative SVEF remained >40%, and no recurrence of significant TR was observed. (4) Conclusions: A stepwise approach combining modern heart failure therapy and elective TV replacement in patients with SRV dysfunction and TR is safe and effective. Preoperative optimization leads to improved ventricular function and may enhance surgical outcomes. These findings support the integration of contemporary pharmacotherapy in the management strategy for SRV failure. Full article
Show Figures

Figure 1

14 pages, 1993 KB  
Article
Reliability of Immersive Virtual Reality for Pre-Procedural Planning for TAVI: A CT-Based Validation
by Nicole Carabetta, Giuseppe Panuccio, Salvatore Giordano, Sabato Sorrentino, Giuseppe Antonio Mazza, Jolanda Sabatino, Giovanni Canino, Isabella Leo, Nadia Salerno, Antonio Strangio, Maria Petullà, Daniele Torella and Salvatore De Rosa
J. Cardiovasc. Dev. Dis. 2025, 12(12), 481; https://doi.org/10.3390/jcdd12120481 - 8 Dec 2025
Viewed by 434
Abstract
Background. Accurate anatomical assessment is essential for pre-procedural planning in structural heart disease. Advanced 3D imaging could offer improved visualization for more accurate reconstruction. We assessed the performance of a novel immersive 3D virtual reality (VEA) for the pre-procedural planning of transcatheter aortic [...] Read more.
Background. Accurate anatomical assessment is essential for pre-procedural planning in structural heart disease. Advanced 3D imaging could offer improved visualization for more accurate reconstruction. We assessed the performance of a novel immersive 3D virtual reality (VEA) for the pre-procedural planning of transcatheter aortic valve implantation (TAVI) candidates. Methods. Measurement of cardiac-gated contrast-enhanced computed tomography (CT) scans was performed with the novel VEA and established tools: 3Mensio and Horos. Results. 50 consecutive patients were included. Annular and LVOT measurements obtained with VEA were strongly correlated with those derived from standard CT analysis. The intraclass correlation coefficient (ICC) confirmed excellent consistency for annular measurements (ICC = 0.93), while the concordance correlation coefficient indicated very good overall agreement (CCC = 0.83, 95% CI 0.73–0.90). Similarly, LVOT measurements obtained with VEA showed strong correlation with CT values, with good consistency (ICC = 0.90) and good overall agreement (CCC = 0.77, 95% CI 0.64–0.86). VEA-based planning improved prosthesis size selection accuracy, achieving higher concordance with implanted valves and a significant net reclassification gain over conventional CT. Conclusions. Given the increasing use of advanced 3D cardiac imaging technologies, understanding their diagnostic accuracy to guide pre-procedural planning of TAVI is paramount. In our study, VEA provided reliable assessment of aortic root anatomy for TAVI planning. This novel 3D software provides accurate, patient-specific reconstructions of the aortic root and surrounding structures that may optimize valve sizing, improve procedural safety and enhance procedural outcomes. This provides a rationale for future studies to assess the procedural benefit derived from a three-dimensional assessment of the aortic valve geometry. Full article
Show Figures

Graphical abstract

10 pages, 779 KB  
Article
Coronary Artery Calcification on Non-Cardiac Gated CT Thorax Scans: A Single Tertiary Centre Retrospective Observational Study
by Robert S. Doyle, Divyanshu Jain, Patrick Devitt, Jack Hartnett, Hugo C. Temperley and Catherine McGorrian
J. Cardiovasc. Dev. Dis. 2025, 12(12), 480; https://doi.org/10.3390/jcdd12120480 - 4 Dec 2025
Viewed by 926
Abstract
Background: While the 2024 ESC Guidelines provide guidance on utilising incidental CAC findings from non-gated CT scans to enhance risk stratification and guide treatment decisions, there remain gaps in detailed protocols for managing such incidental findings, particularly in inpatient settings. An incidental finding [...] Read more.
Background: While the 2024 ESC Guidelines provide guidance on utilising incidental CAC findings from non-gated CT scans to enhance risk stratification and guide treatment decisions, there remain gaps in detailed protocols for managing such incidental findings, particularly in inpatient settings. An incidental finding of CAC in a patient without known atherosclerosis provides an opportunity to assess cardiac risk, promote risk factor optimisation and evaluate need for further cardiac work up. The aim of this study was to assess the prevalence of incidental coronary artery calcification on non-cardiac dedicated gated CT thorax scans among general medical inpatients and to evaluate the subsequent management of these findings. Methods: This was a single-centre retrospective observational study of consecutive general medical inpatients aged 40–75, who had undergone a non-cardiac gated CT thorax during their admission, between February and March 2025. Data were collected using local electronic health records. Exclusion criteria were patients with known ischaemic heart disease (IHD). Risk factor assessment was noted by documentation of smoking status, hypertension, diabetes and low-density lipoprotein (LDL) values. Results: A total of 186 patients with thoracic CT scans were identified. On review of all CT reports, 53 (28.4%) patients had CAC reported, of whom 17 had known IHD. Therefore 36 (19.4%) patients were identified for further analysis. An exercise stress test was booked in none of the patients. A coronary angiogram was booked in 1 patient. Conclusions: One fifth of medical inpatients in our study had a new finding of CAC on thoracic imaging. Cardiovascular risk factors of LDL and HbA1c were checked in less than half of patients. None of these patients went on to have functional testing. There is a valuable opportunity to optimise cardiac risk factors and evaluate the need for functional testing in a subset of patients with CAC reported on non-cardiac CTs. This can be facilitated by raising awareness and implementing a flowchart tool for hospital physicians to reference. Full article
Show Figures

Figure 1

13 pages, 2180 KB  
Review
Atrioventricular Junction Ablation with High-Definition Recording of Atrioventricular Node Potential
by Andrea Matteucci, Enrico Maggio, Domenico Dardani, Maurizio Russo, Marco Galeazzi, Federico Nardi, Silvio Fedele, Claudio Pandozi and Furio Colivicchi
J. Cardiovasc. Dev. Dis. 2025, 12(12), 479; https://doi.org/10.3390/jcdd12120479 - 4 Dec 2025
Viewed by 328
Abstract
Atrioventricular (AV) node ablation represents an established therapeutic option in the management of atrial fibrillation (AF) and other atrial tachyarrhythmias, particularly in patients with symptomatic tachycardia who remain unresponsive or intolerant to pharmacological therapy. The procedure is often considered in cases of refractory [...] Read more.
Atrioventricular (AV) node ablation represents an established therapeutic option in the management of atrial fibrillation (AF) and other atrial tachyarrhythmias, particularly in patients with symptomatic tachycardia who remain unresponsive or intolerant to pharmacological therapy. The procedure is often considered in cases of refractory arrhythmias, antiarrhythmic drugs intolerance, or tachycardiomyopathy, and plays a key role in optimizing outcomes in patients undergoing cardiac resynchronization therapy, where achieving adequate biventricular pacing is otherwise compromised by rapid ventricular responses. Traditionally, AV node ablation is performed using radiofrequency energy delivered at the region of the His bundle, guided by the earliest His potential recordings. However, the anatomical complexity of the AV node and Koch’s triangle poses important challenges, including the risk of incomplete ablation, persistence of conduction, lack of reliable junctional escape rhythms, and increased risk of proarrhythmia. Recent advances in high-resolution mapping and electroanatomical guidance have enabled a more precise anatomical approach, selectively targeting the compact AV node while reducing collateral injury. These developments offer the potential for improved procedural safety, long-term efficacy, and a more standardized strategy for patient management. This review summarizes current evidence, techniques, and clinical implications of AV node ablation, highlighting its role in the evolving landscape of arrhythmia treatment. Full article
Show Figures

Graphical abstract

11 pages, 793 KB  
Article
Effects of a Novel Hippophae rhamnoides L. Seed Lipid Extract Formulation Obtained via Supercritical Carbon Dioxide Extraction on Reducing Residual Cardiovascular Risk in High-Risk Patients: A Pilot Study
by Kristaps Erglis, Baiba Kokina, Sanda Jegere, Iveta Mintale, Eriks Jakobsons, Vadims Bartkevics, Martins Erglis, Ralfs Zuzans, Inga Narbute, Karlis Trusinskis and Andrejs Erglis
J. Cardiovasc. Dev. Dis. 2025, 12(12), 478; https://doi.org/10.3390/jcdd12120478 - 4 Dec 2025
Viewed by 559
Abstract
Unsaturated fatty acids have the potential to reduce residual cardiovascular risk. Sea buckthorn (Hippophae rhamnoides L.) contains several valuable bioactive substances, including lipids with a balanced fatty acid composition. The aim of this study was to evaluate the effects of sea buckthorn [...] Read more.
Unsaturated fatty acids have the potential to reduce residual cardiovascular risk. Sea buckthorn (Hippophae rhamnoides L.) contains several valuable bioactive substances, including lipids with a balanced fatty acid composition. The aim of this study was to evaluate the effects of sea buckthorn seed lipid extract (SBS-LE) on residual cardiovascular risk in high-risk patients. In this pilot study, 86 patients with chronic coronary syndrome receiving statin (atorvastatin or rosuvastatin) and/or ezetimibe were enrolled. SBS-LE capsules (1000 mg, twice daily) were prescribed in addition to standard medical therapy, with each capsule containing 300 mg of omega-3 alpha-linolenic acid, 370 mg of omega-6 linoleic acid, 170 mg of omega-9 oleic acid and 7 mg of the plant sterol beta-sitosterol. For this clinical trial, SBS-LE was produced via supercritical fluid extraction with carbon dioxide. Clinical effects and impacts on laboratory test results were evaluated at baseline and after three months. Additionally, lipidomics testing was performed to confirm the bioavailability of the formulation. Significant reductions in systolic blood pressure by 2.9 mmHg (2.1%, p = 0.012), LDL-C by 0.3 mmol/l (12.0%, p = 0.005) and CRP by 1.0 mg/l (37.0%, p = 0.032) were observed. These data suggest that SBS-LE may have potential as an add-on preventive strategy for residual cardiovascular risk reduction. Full article
(This article belongs to the Special Issue Cardiovascular Disease and Nutrition)
Show Figures

Figure 1

6 pages, 959 KB  
Case Report
Superior Vena Cava Approach for Farapulse Pulsed-Field Ablation in Patient with Paroxysmal Atrial Fibrillation: A Case Report
by Qitong Zhang, Linhua Kuang, Xiaoyu Wu, Zikan Zhong, Shaowen Liu and Genqing Zhou
J. Cardiovasc. Dev. Dis. 2025, 12(12), 477; https://doi.org/10.3390/jcdd12120477 - 4 Dec 2025
Viewed by 606
Abstract
Background: Catheter ablation of atrial fibrillation (AF) is now a Class I recommendation therapy. However, the standard inferior vena cava (IVC) approach of catheter ablation is not feasible in all patients. Case presentation: We report a case of a 64-year-old woman [...] Read more.
Background: Catheter ablation of atrial fibrillation (AF) is now a Class I recommendation therapy. However, the standard inferior vena cava (IVC) approach of catheter ablation is not feasible in all patients. Case presentation: We report a case of a 64-year-old woman in whom guidewire passage was hindered by prior left iliac vein stent placement and with symptomatic recurrent paroxysmal AF who underwent successful pulmonary vein isolation with a pulsed-field ablation system by superior vena cava (SVC) access from the right internal jugular vein. Conclusions: PFA administered via the SVC provides an effective and efficient treatment strategy for patients with paroxysmal AF ineligible for standard IVC catheter ablation. Full article
Show Figures

Figure 1

15 pages, 2145 KB  
Article
Echocardiographic Predictors of Ventricular Arrhythmias Post-Automatic Implantable Cardioverter–Defibrillator Implantation
by Mehmet Harapoz, Yan Stanislaw Andrzej Zochowski, Siddharth J. Trivedi, Saurabh Kumar and Liza Thomas
J. Cardiovasc. Dev. Dis. 2025, 12(12), 476; https://doi.org/10.3390/jcdd12120476 - 3 Dec 2025
Viewed by 380
Abstract
(1) Background: Ventricular arrhythmias (VAs) are a leading cause of morbidity and mortality in ischemic and non-ischemic heart disease. While automated implantable cardioverter–defibrillators (AICDs) are standard treatment for high-risk patients, predicting future VA post-implantation remains limited. This study evaluated echocardiographic and strain parameters [...] Read more.
(1) Background: Ventricular arrhythmias (VAs) are a leading cause of morbidity and mortality in ischemic and non-ischemic heart disease. While automated implantable cardioverter–defibrillators (AICDs) are standard treatment for high-risk patients, predicting future VA post-implantation remains limited. This study evaluated echocardiographic and strain parameters for predicting VA risk in AICD recipients. (2) Methods: This retrospective cohort study included patients who underwent AICD implantation at Westmead Hospital, New South Wales, Australia (January 2014–May 2024). Pre-implant transthoracic echocardiograms (TTEs) were analysed for structural and functional parameters, including left-ventricular (LV) ejection fraction (LVEF), LV global longitudinal strain (GLS), mechanical dispersion (MD), and delta contraction duration (DCD). VA events, defined as appropriate AICD shock or anti-tachycardia pacing, were identified from electronic medical records and device checks. Univariate and multivariate Cox regression analyses were performed. (3) Results: Among 242 patients, 98 experienced VA events. Increased LV end-diastolic diameter, indexed LV mass, and right-ventricular basal diameter were associated with VA events (p < 0.05), whilst LVEF and GLS were not. LV dyssynchrony was greater in affected patients (MD 69.2 ms vs. 63 ms, p = 0.036; DCD 288.8 ms vs. 246.4 ms, p = 0.010). DCD was an independent predictor of VA events (HR 1.003; 95% CI: 1.000–1.006; p = 0.022). (4) Conclusions: DCD may improve risk stratification in AICD patients. Full article
(This article belongs to the Section Imaging)
Show Figures

Figure 1

22 pages, 3332 KB  
Review
A Contemporary Guide of Venoarterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock
by Vinh Q. Chau, George Kalapurakal, Teruhiko Imamura, Ben B. Chung, Sejal Loberg, Allison Beckett, Antone J. Tatooles and Nikhil Narang
J. Cardiovasc. Dev. Dis. 2025, 12(12), 475; https://doi.org/10.3390/jcdd12120475 - 2 Dec 2025
Viewed by 1826
Abstract
Managing refractory cardiogenic shock is individualized, with few aspects considered routine or universally contraindicated. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a temporary mechanical circulatory support strategy, providing hemodynamic stabilization and gas exchange for patients with severe cardiogenic shock. It is increasingly used as [...] Read more.
Managing refractory cardiogenic shock is individualized, with few aspects considered routine or universally contraindicated. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a temporary mechanical circulatory support strategy, providing hemodynamic stabilization and gas exchange for patients with severe cardiogenic shock. It is increasingly used as salvage therapy for advanced cardiopulmonary failure and serves as a bridge to myocardial recovery, heart transplantation, or durable mechanical support such as a left ventricular assist device. Over the past decade, VA-ECMO utilization has risen, even though robust clinical trial evidence supporting its use remains limited. Furthermore, consensus is lacking on key aspects of care, including patient selection, cannulation strategy, weaning protocols, and complication management. This review outlines a structured approach to daily VA-ECMO care, emphasizing multidisciplinary coordination and individualized patient support to optimize outcomes and mitigate complications. We also address the implications of limited trial data and highlight the need for evidence-based frameworks to guide clinical decision-making. Full article
Show Figures

Figure 1

25 pages, 1437 KB  
Review
The Irreversible March of Time: Ischemic Delay and Impact on Outcomes in ST-Segment Elevation Myocardial Infarction
by Artur Dziewierz, Barbara Zdzierak, Wojciech Wańha, Giuseppe De Luca and Tomasz Rakowski
J. Cardiovasc. Dev. Dis. 2025, 12(12), 474; https://doi.org/10.3390/jcdd12120474 - 2 Dec 2025
Viewed by 1160
Abstract
ST-segment elevation myocardial infarction (STEMI) represents a time-critical medical emergency where complete coronary artery occlusion initiates progressive myocardial necrosis. The fundamental principle of modern STEMI care—“Time is Muscle”—establishes that ischemic duration directly determines infarct size and clinical outcomes. Each minute of delay correlates [...] Read more.
ST-segment elevation myocardial infarction (STEMI) represents a time-critical medical emergency where complete coronary artery occlusion initiates progressive myocardial necrosis. The fundamental principle of modern STEMI care—“Time is Muscle”—establishes that ischemic duration directly determines infarct size and clinical outcomes. Each minute of delay correlates with increased mortality, larger infarcts, and a higher risk of heart failure development. Total ischemic time encompasses both patient-mediated delays (often the largest component) and system-related delays, each influenced by distinct factors requiring targeted interventions. This comprehensive review analyzes the components of total ischemic time, quantifies the clinical consequences of delay, and evaluates evidence-based mitigation strategies. We examine the evolution from fibrinolysis to primary percutaneous coronary intervention and the resulting logistical challenges. System-level interventions—including public awareness campaigns, regionalized STEMI networks, pre-hospital ECG acquisition, and standardized hospital protocols—have dramatically reduced treatment times. However, persistent disparities based on geography, presentation timing, sex, race, and age remain problematic. Emerging technologies, particularly artificial intelligence for ECG interpretation, offer promise for further time reduction. Full article
Show Figures

Figure 1

17 pages, 7682 KB  
Review
Cardiac Computed Tomography: Technological Developments and Clinical Applications
by Katsuya Suzuki, Hiroyuki Takaoka, Ryosuke Irie, Moe Matsumoto, Yoshitada Noguchi, Shuhei Aoki, Kazuki Yoshida, Haruto Matsumoto, Satomi Yashima, Makiko Kinoshita, Haruka Sasaki, Noriko Suzuki-Eguchi and Yoshio Kobayashi
J. Cardiovasc. Dev. Dis. 2025, 12(12), 473; https://doi.org/10.3390/jcdd12120473 - 2 Dec 2025
Viewed by 873
Abstract
Cardiac computed tomography (CT) has long evolved as a highly accurate screening tool for coronary artery disease. New technologies such as multi-detector rows and artifact reduction by a new motion correction algorithm have made it possible to evaluate coronary artery stenosis with higher [...] Read more.
Cardiac computed tomography (CT) has long evolved as a highly accurate screening tool for coronary artery disease. New technologies such as multi-detector rows and artifact reduction by a new motion correction algorithm have made it possible to evaluate coronary artery stenosis with higher diagnostic accuracy and lower radiation exposure. In addition to the anatomical evaluation of coronary arteries, the introduction of fluid dynamic analysis enables the measurement of coronary fractional flow reserve (FFR) for each stenotic lesion, which can only be achieved through invasive catheter evaluation. Myocardial ischemia can now also be detected using myocardial stress perfusion CT imaging. In addition, with the advent of dual-energy imaging or new image reconstruction technology, the addition of late contrast phase imaging enables myocardial late enhancement and left ventricular (LV) extracellular volume (ECV) analysis, which was previously possible only with cardiac magnetic resonance imaging (MRI). It has also been reported that LV ECV may be useful in predicting prognosis in cases with cardiomyopathies. In addition, retrospective imaging of the entire heart in a single cardiac cycle is now possible with lower radiation exposure, enabling not only morphological evaluation of the heart and valves but also myocardial strain analysis, which has conventionally been evaluated mainly by echocardiography and is expected to be applied in clinical practice in the future. Cardiac CT, which overcomes the weaknesses of other modalities while demonstrating greater usefulness through the latest technological development, is expected to expand its field of application to the entire heart analysis. The purpose of this review is to provide an overview of the technological development of cardiac CT, which has seen remarkable development in recent years, along with its clinical utility, with the aim of enabling clinicians to fully utilize it in daily practice. Full article
(This article belongs to the Topic Cardiac Imaging: State of the Art, 2nd Edition)
Show Figures

Figure 1

15 pages, 2144 KB  
Review
Percutaneous Treatment of Mitral Regurgitation After Failed Mitral Transcatheter Edge-to-Edge Repair
by André González-García, Julio Echarte-Morales, Manuel Barreiro-Pérez, José Antonio Baz-Alonso, Andrés Íñiguez-Romo and Rodrigo Estévez-Loureiro
J. Cardiovasc. Dev. Dis. 2025, 12(12), 472; https://doi.org/10.3390/jcdd12120472 - 30 Nov 2025
Viewed by 473
Abstract
Mitral regurgitation is one of the most prevalent valvular heart diseases globally and the second most common indication for cardiac valve surgery, surpassed only by aortic stenosis. Over the past decades, open-heart mitral valve surgery has been the gold-standard intervention for this complex [...] Read more.
Mitral regurgitation is one of the most prevalent valvular heart diseases globally and the second most common indication for cardiac valve surgery, surpassed only by aortic stenosis. Over the past decades, open-heart mitral valve surgery has been the gold-standard intervention for this complex disorder, but in recent years, transcatheter edge-to-edge repair has emerged as a valuable option in selected clinical scenarios. However, a considerable proportion of patients develop recurrent mitral regurgitation during follow-up, leading to a significant increase in morbidity and mortality. In this context, data is limited regarding the optimal approach. This review provides an overview of the current evidence on transcatheter mitral valve intervention therapies for the management of recurrent mitral regurgitation following transcatheter edge-to-edge repair. Full article
Show Figures

Figure 1

Previous Issue
Next Issue
Back to TopTop